MCID: THR014
MIFTS: 66

Thrombocytopenia

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia

Summaries for Thrombocytopenia

KEGG : 36 Thrombocytopenia is defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. Inherited syndromes are relatively rare causes of thrombocytopenia, but some genes underlying these disorders have been elucidated. Some inherited syndromes predispose to the development of bone marrow failure or leukemia. For example, familial platelet disorder with associated myeloid malignancy (FPDMM) is characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.

MalaCards based summary : Thrombocytopenia is related to thrombocytopenia-absent radius syndrome and thrombocytopenic purpura, autoimmune. An important gene associated with Thrombocytopenia is ANKRD26 (Ankyrin Repeat Domain 26), and among its related pathways/superpathways are Tight junction and NF-kappaB Signaling. The drugs Certoparin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and breast, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A blood platelet disease that is characterized by low a platelet count in the blood.

PubMed Health : 62 About thrombocytopenia: Thrombocytopenia (THROM-bo-si-to-PE-ne-ah) is a condition in which your blood has a lower than normal number of blood cell fragments called platelets (PLATE-lets). Platelets are made in your bone marrow along with other kinds of blood cells. They travel through your blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes (THROM-bo-sites) because a clot also is called a thrombus.

Wikipedia : 74 Thrombocytopenia is a condition characterized by abnormally low levels of platelets, also known as... more...

Related Diseases for Thrombocytopenia

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Thrombocytopenia 7 Acquired Thrombocytopenia
Thrombocytopenia Due to Platelet Alloimmunization Primary Thrombocytopenia
Ankrd26-Related Thrombocytopenia

Diseases related to Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1549)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia-absent radius syndrome 33.8 SLFN14 NBEAL2 MPL GFI1B ANKRD26
2 thrombocytopenic purpura, autoimmune 33.2 MPL ITGA2B ADAMTS13
3 bernard-soulier syndrome 33.1 VWF SEPT5-GP1BB NBEAL2 MYH9 MPL ITGA2B
4 acquired thrombocytopenia 32.8 MYH9 MPL ITGA2B F11 ANKRD26
5 platelet disorder, familial, with associated myeloid malignancy 32.8 RUNX1 ETV6 ANKRD26
6 primary thrombocytopenia 32.7 VWF MPL ITGA2B ADAMTS13
7 blood platelet disease 32.7 WAS VWF RUNX1 NBEAL2 MYH9 MPL
8 purpura 32.6 VWF MPL ITGA2B ADAMTS13
9 gray platelet syndrome 32.6 VWF NBEAL2 MYH9 ITGA2B GFI1B
10 ankrd26-related thrombocytopenia 32.6 MYH9 ANKRD26
11 etv6 thrombocytopenia and predisposition to leukemia 32.5 RUNX1 ETV6
12 myh-9 related disease 32.3 MYH9 MPL ANKRD26 ACTN1
13 thrombotic microangiopathy 32.2 VWF ADAMTS13
14 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 32.0 RUNX1 ETV6
15 thrombosis 31.9 VWF ITGA2B F11 ADAMTS13
16 storage pool platelet disease 31.9 RUNX1 GFI1B
17 myelodysplastic syndrome 31.8 RUNX1 MPL ITGA2B ETV6 CHEK2 ANKRD26
18 splenic sequestration 31.5 VWF MPL ITGA2B ADAMTS13
19 von willebrand's disease 31.4 VWF ITGA2B F11 ADAMTS13
20 autosomal dominant macrothrombocytopenia 31.3 MYH9 ITGA2B GFI1B ACTN1
21 myeloproliferative neoplasm 31.2 VWF RUNX1 MPL ETV6
22 leukemia, acute myeloid 31.2 RUNX1 MPL ITGA2B ETV6 CHEK2
23 essential thrombocythemia 31.1 VWF MPL ITGA2B CHEK2
24 hemorrhagic disease 31.0 VWF SMAD4 SLFN14 RUNX1 NBEAL2 MYH9
25 refractory anemia 30.8 RUNX1 MPL
26 kaposiform hemangioendothelioma 30.5 VWF FLI1
27 intracranial thrombosis 30.5 VWF ITGA2B F11
28 acute megakaryocytic leukemia 30.5 RUNX1 MPL ITGA2B
29 von willebrand disease, type 2 30.3 VWF ADAMTS13
30 angiodysplasia 30.1 VWF ADAMTS13
31 carotid artery thrombosis 30.0 VWF ITGA2B F11
32 hemarthrosis 29.9 VWF F11
33 thrombocytopenia due to platelet alloimmunization 11.8
34 thrombocytopenia 1 11.7
35 amegakaryocytic thrombocytopenia, congenital 11.7
36 heparin-induced thrombocytopenia 11.6
37 thrombocytopenia with beta-thalassemia, x-linked 11.6
38 dyserythropoietic anemia and thrombocytopenia 11.6
39 macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss 11.5
40 thrombocytopenia 2 11.5
41 thrombocytopenia 5 11.5
42 wiskott-aldrich syndrome 11.5
43 radioulnar synostosis with amegakaryocytic thrombocytopenia 1 11.5
44 fetal and neonatal alloimmune thrombocytopenia 11.5
45 thrombocytopenia 3 11.5
46 thrombocytopenia, paris-trousseau type 11.5
47 hemangioma-thrombocytopenia syndrome 11.5
48 thrombocytopenia 6 11.4
49 thrombocytopenia 4 11.4
50 thrombocytopenia, x-linked, with or without dyserythropoietic anemia 11.4

Graphical network of the top 20 diseases related to Thrombocytopenia:



Diseases related to Thrombocytopenia

Symptoms & Phenotypes for Thrombocytopenia

MGI Mouse Phenotypes related to Thrombocytopenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CHEK2 ETV6 F11 FLI1 GFI1B ITGA2B
2 cardiovascular system MP:0005385 10.11 ANKRD26 CHEK2 ETV6 F11 FLI1 GFI1B
3 hematopoietic system MP:0005397 10.1 ADAMTS13 CHEK2 ETV6 F11 FLI1 GFI1B
4 homeostasis/metabolism MP:0005376 10 ADAMTS13 ANKRD26 CHEK2 ETV6 F11 GFI1B
5 immune system MP:0005387 9.8 ADAMTS13 CHEK2 ETV6 F11 FLI1 GFI1B
6 neoplasm MP:0002006 9.17 CHEK2 ETV6 FLI1 NBEAL2 RUNX1 SMAD4

Drugs & Therapeutics for Thrombocytopenia

PubMed Health treatment related to Thrombocytopenia: 62

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding . If your condition is mild, you may not need treatment . A fully normal platelet count isn't necessary to prevent bleeding , even with severe cuts or accidents. Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition usually don't need treatment . If a reaction to a medicine is causing a low platelet count, your doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin -induced thrombocytopenia (HIT), stopping the heparin isn't enough. Often, you'll need another medicine to prevent blood clotting . If your immune system is causing a low platelet count, your doctor may prescribe medicines to suppress the immune system.

Drugs for Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 295)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Certoparin Approved, Investigational Phase 4
2
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
3
Oprelvekin Approved, Investigational Phase 4 145941-26-0
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Clarithromycin Approved Phase 4 81103-11-9 84029
8
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
9
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
10
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
11
Ribavirin Approved Phase 4 36791-04-5 37542
12
Desirudin Approved Phase 4 120993-53-5
13
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
14
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
15
Enoxolone Investigational Phase 4 471-53-4 18526330
16 Antiparasitic Agents Phase 4
17 Antiprotozoal Agents Phase 4
18 Antimalarials Phase 4
19
Caffeic acid Phase 4 331-39-5, 501-16-6 689043
20 Autoantibodies Phase 4
21 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
22 Hypolipidemic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Anticholesteremic Agents Phase 4
25 Tin Fluorides Phase 4
26 Nutrients Phase 4
27 Micronutrients Phase 4
28 Trace Elements Phase 4
29 Vitamins Phase 4
30 Calcium, Dietary Phase 4
31 Calciferol Phase 4
32 Vasoconstrictor Agents Phase 4
33 Protective Agents Phase 4
34 Antioxidants Phase 4
35 Liver Extracts Phase 4
36
Bilirubin Phase 4 635-65-4 5280352
37 Immunoglobulins, Intravenous Phase 4
38 gamma-Globulins Phase 4
39 Rho(D) Immune Globulin Phase 4
40 interferons Phase 4
41
Calcium Nutraceutical Phase 4 7440-70-2 271
42
Warfarin Approved Phase 3 81-81-2 6691 54678486
43
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
44
Dapsone Approved, Investigational Phase 3 80-08-0 2955
45
Pantoprazole Approved Phase 3 102625-70-7 4679
46
Metronidazole Approved Phase 3 443-48-1 4173
47
Ifosfamide Approved Phase 3 3778-73-2 3690
48
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
49
Tranexamic Acid Approved Phase 3 1197-18-8 5526
50
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 516)
# Name Status NCT ID Phase Drugs
1 High-dose Use of Recombinant Human Thrombopoietin in Patients With Moderate or Severe Thrombocytopenia Induced by Chemotherapy Unknown status NCT03633019 Phase 4 rhTPO
2 Sirolimus in Patients With Connective Tissue Disease Related Thrombocytopenia (CTD-TP): a Single-arm, Open-label Clinical Trial in China Unknown status NCT03688191 Phase 4 Sirolimus
3 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
4 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
5 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
6 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
7 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
8 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
9 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
10 Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process Completed NCT01789762 Phase 4
11 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
12 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
13 Bicentric Clinical Trial With in Vitro Experiments to Assess the Effect of Fibrinogen (FGTW) on Coagulation in Thrombocytopenia Completed NCT01955811 Phase 4 Administration of platelet concentrate and taking blood samples
14 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
15 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
16 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
17 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
18 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
19 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
20 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
21 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
22 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
23 A Prospective, Single-center Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia Recruiting NCT04226950 Phase 4 Recombinant Interferon Alpha;Pegylated interferon alfa-2b
24 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Recruiting NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
25 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
26 Thromboprophylaxis With Fondaparinux of Deep Vein Thrombosis and Pulmonary Embolism in the Acutely-ill Medical Inpatients With Thrombocytopenia Active, not recruiting NCT01727401 Phase 4 Fondaparinux
27 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
28 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
29 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Not yet recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
30 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
31 Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial Terminated NCT00798525 Phase 4 Argatroban;Lepirudin
32 Experimental Protocol for the Infusion of Platelets,Cryopreserved With Dimethyl Sulphoxide (DMSO) and Obtained From Multiple Donors Buffy Coats, in Patients With Severe Thrombocytopenia Terminated NCT02032134 Phase 4
33 The Safety and Efficacy of Intravenous Anti-D for the Treatment of Thrombocytopenia in Patients With HCV Infection Prior to or During Treatment With Pegylated-interferon and Ribavirin Terminated NCT00239733 Phase 4 Anti-D
34 A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS) Terminated NCT00787332 Phase 4 Desirudin or Argatroban®
35 Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia Withdrawn NCT00603824 Phase 4 fondaparinux;argatroban or lepirudin
36 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
37 Bivalirudin PCI Registry in HIT/HITTS Patients Withdrawn NCT00759083 Phase 4 bivalirudin
38 A Phase IV Study Evaluating Eltrombopag Concentrations in Breast Milk of Nursing Mothers Taking Eltrombopag Withdrawn NCT01055600 Phase 4 eltrombopag
39 Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus Unknown status NCT02444728 Phase 3 Hydroxychloroquine;Cyclophosphamide;Azathioprine;Methylprednisolone
40 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
41 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
42 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
43 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
44 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
45 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
46 A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Unknown status NCT03164915 Phase 3
47 Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT) Unknown status NCT03147638 Phase 3 Warfarin, NOAC
48 A Randomized, Open-label, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of Recombinant Human Thrombopoietin Among Severe Sepsis Patients With Thrombocytopenia Unknown status NCT02094248 Phase 2, Phase 3 TPO;control
49 A Randomized, Double Blind Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Solid Tumor Unknown status NCT02093325 Phase 3 Eltrombopag;Placebo
50 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication

Search NIH Clinical Center for Thrombocytopenia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Thrombocytopenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: thrombocytopenia

Genetic Tests for Thrombocytopenia

Genetic tests related to Thrombocytopenia:

# Genetic test Affiliating Genes
1 Thrombocytopenia 29

Anatomical Context for Thrombocytopenia

MalaCards organs/tissues related to Thrombocytopenia:

40
Bone Marrow, Myeloid, Breast, Kidney, Spleen, Liver, Skin

Publications for Thrombocytopenia

Articles related to Thrombocytopenia:

(show top 50) (show all 30467)
# Title Authors PMID Year
1
Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats. 54 61
19705256 2010
2
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 61 54
20175767 2010
3
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. 54 61
20181616 2010
4
The prothrombotic potential of platelet factor 4. 54 61
20206875 2010
5
Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. 54 61
20430179 2010
6
Proteinase-activated receptor (PAR1) polymorphic variant correlates with thrombocytopenia in Gaucher disease. 61 54
19969492 2010
7
A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers. 61 54
19740526 2010
8
Serum thrombopoietin level and thrombocytopenia during the neonatal period in infants with Down's syndrome. 54 61
19675574 2010
9
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. 61 54
20203368 2010
10
Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. 61 54
19709391 2010
11
Heparin-induced thrombocytopenia. 61 54
20059332 2010
12
Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations. 54 61
19451811 2010
13
Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. 61 54
19679353 2010
14
Infectious causes of chronic immune thrombocytopenia. 54 61
19932434 2009
15
Heparin induced thrombocytopenia in a patient with factor V Leiden following cardiac surgery. 61 54
19783545 2009
16
An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. 54 61
19409826 2009
17
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura. 54 61
19786614 2009
18
Intracranial hemorrhage in dengue fever: management and outcome: a series of 5 cases and review of literature. 54 61
19328535 2009
19
Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene. 61 54
19337732 2009
20
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. 54 61
19671919 2009
21
[Two Crimean-Congo hemorrhagic fever cases without history of tick contact from Ankara region]. 61 54
20084924 2009
22
Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni. 54 61
19118853 2009
23
Thrombopoietin receptor agonists in the treatment of thrombocytopenia. 54 61
19553811 2009
24
Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. 61 54
19698012 2009
25
Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid. 61 54
19801810 2009
26
Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies. 61 54
19497062 2009
27
Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. 61 54
19473438 2009
28
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. 61 54
19494352 2009
29
Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. 61 54
19628164 2009
30
Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. 61 54
19572073 2009
31
Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. 54 61
19200137 2009
32
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. 54 61
19195684 2009
33
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. 61 54
19351959 2009
34
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. 54 61
19207581 2009
35
Identification of a predictive biomarker for hematologic toxicities of gemcitabine. 61 54
19289617 2009
36
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia. 61 54
19252138 2009
37
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. 54 61
19037596 2009
38
An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. 61 54
19452409 2009
39
Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature. 54 61
19302922 2009
40
Prevalence of heparin-induced antibody in African-American hemodialysis patients--comparison to non-dialysis patients. 54 61
19281736 2009
41
Clinical implications of alpha-fetoprotein in chronic hepatitis C. 54 61
19293036 2009
42
Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. 61 54
19055667 2009
43
[The analysis of thrombopoietin and clinical parameters as a marker for disease progression in patients with multiple myeloma]. 61 54
19262084 2009
44
Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. 61 54
18796624 2009
45
Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. 54 61
19245931 2009
46
Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia. 54 61
19126826 2009
47
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. 54 61
19642221 2009
48
HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. 54 61
19038456 2009
49
Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. 61 54
19260037 2009
50
Thrombocytopenia with absent radii (TAR) syndrome: from hemopoietic progenitor to mesenchymal stromal cell disease? 61 54
19028006 2009

Variations for Thrombocytopenia

ClinVar genetic disease variations for Thrombocytopenia:

6 (show top 50) (show all 349)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ETV6 NM_001987.4(ETV6):c.1046T>C (p.Leu349Pro) SNV Pathogenic 190241 rs786205155 12:12037415-12037415 12:11884481-11884481
2 ETV6 NM_001987.4(ETV6):c.1046T>C (p.Leu349Pro) SNV Pathogenic 190241 rs786205155 12:12037415-12037415 12:11884481-11884481
3 ETV6 NM_001987.4(ETV6):c.1153-5_1153-1del Microsatellite Pathogenic 190240 12:12038855-12038859 12:11885921-11885925
4 ETV6 NM_001987.4(ETV6):c.1153-5_1153-1del Microsatellite Pathogenic 190240 12:12038855-12038859 12:11885921-11885925
5 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs) Deletion Pathogenic 128042 rs555607708 22:29091857-29091857 22:28695869-28695869
6 NIPA1 GRCh37/hg19 15q11.2(chr15:22765628-23300287) copy number loss Pathogenic 523249 15:22765628-23300287
7 ANKRD26 NM_014915.2(ANKRD26):c.-126T>C SNV Pathogenic 626941 rs1589393792 10:27389381-27389381 10:27100452-27100452
8 ANKRD26 NM_014915.2(ANKRD26):c.-127A>G SNV Pathogenic 626942 rs1589393799 10:27389382-27389382 10:27100453-27100453
9 ITGA2B NM_000419.5(ITGA2B):c.3076C>T (p.Arg1026Trp) SNV Pathogenic 50233 rs766503255 17:42449776-42449776 17:44372408-44372408
10 WAS NM_000377.2(WAS):c.134C>T (p.Thr45Met) SNV Pathogenic 11123 rs132630273 X:48542673-48542673 X:48684284-48684284
11 ACTN1 NM_001102.4(ACTN1):c.136C>T (p.Arg46Trp) SNV Pathogenic 626995 rs747559032 14:69392359-69392359 14:68925642-68925642
12 SEPT5-GP1BB NM_000407.4(GP1BB):c.143C>A (p.Ser48Ter) SNV Pathogenic 627237 rs536874549 22:19711509-19711509 22:19723986-19723986
13 ANKRD26 NM_014915.3(ANKRD26):c.-128G>A SNV Pathogenic 812727 rs1589393809 10:27389383-27389383 10:27100454-27100454
14 RUNX1 NC_000021.9:g.34791392_34804065del Deletion Pathogenic 812915 21:36163689-36176362
15 RUNX1 NC_000021.8:g.36284364_37074805del Deletion Pathogenic 812916 21:36284364-37074805
16 RUNX1 NC_000021.8:g.36323351_37470324del Deletion Pathogenic 812918 21:36323351-37470324
17 RUNX1 NM_001754.5(RUNX1):c.508+1G>T SNV Pathogenic 988808 21:36252853-36252853 21:34880556-34880556
18 RUNX1 NM_001754.5(RUNX1):c.98-1G>A SNV Pathogenic 988809 21:36259394-36259394 21:34887097-34887097
19 VWF NM_000552.4(VWF):c.7390C>T (p.Arg2464Cys) SNV Pathogenic 100467 rs61751286 12:6085324-6085324 12:5976158-5976158
20 SLFN14 NM_001129820.2(SLFN14):c.3_4insCTAGTCGACTATA (p.Glu2fs) Insertion Pathogenic 988815 17:33885078-33885079 17:35558059-35558060
21 ADAMTS13 NM_139027.6(ADAMTS13):c.1315G>T (p.Glu439Ter) SNV Pathogenic 988818 9:136301955-136301955 9:133436835-133436835
22 GFI1B NM_001377304.1(GFI1B):c.814+1G>A SNV Pathogenic 988821 9:135865295-135865295 9:132989908-132989908
23 ETV6 NM_001987.5(ETV6):c.1288C>T (p.Arg430Ter) SNV Pathogenic 988827 12:12043909-12043909 12:11890975-11890975
24 VWF NM_000552.4(VWF):c.2516del (p.Gly839fs) Deletion Pathogenic 100225 rs61748481 12:6145584-6145584 12:6036418-6036418
25 NBEAL2 NM_015175.3(NBEAL2):c.6801+1G>C SNV Pathogenic 988824 3:47047338-47047338 3:47005848-47005848
26 FLI1 NM_002017.5(FLI1):c.992_995del (p.Asn331fs) Deletion Pathogenic 424634 rs1064797085 11:128680515-128680518 11:128810620-128810623
27 ITGA2B NM_000419.5(ITGA2B):c.2176A>T (p.Lys726Ter) SNV Pathogenic 988822 17:42455077-42455077 17:44377709-44377709
28 RUNX1 NM_001754.5(RUNX1):c.351+1G>T SNV Pathogenic 988837 21:36259139-36259139 21:34886842-34886842
29 F11 NM_000128.3(F11):c.403G>T (p.Glu135Ter) SNV Pathogenic 11891 rs121965063 4:187195347-187195347 4:186274193-186274193
30 RUNX1 NM_001754.5(RUNX1):c.317G>A (p.Trp106Ter) SNV Pathogenic 988835 21:36259174-36259174 21:34886877-34886877
31 MYH9 NM_002473.5(MYH9):c.5797C>T (p.Arg1933Ter) SNV Pathogenic 14072 rs80338835 22:36678800-36678800 22:36282754-36282754
32 MYH9 NM_002473.5(MYH9):c.3493C>T (p.Arg1165Cys) SNV Pathogenic 14074 rs80338829 22:36691115-36691115 22:36295069-36295069
33 ETV6 NM_001987.4(ETV6):c.1195C>T (p.Arg399Cys) SNV Pathogenic 162220 rs724159945 12:12038902-12038902 12:11885968-11885968
34 ETV6 NM_001987.4(ETV6):c.1106G>A (p.Arg369Gln) SNV Pathogenic 162221 rs724159946 12:12037475-12037475 12:11884541-11884541
35 MPL NM_005373.2(MPL):c.305G>C (p.Arg102Pro) SNV Pathogenic 14158 rs28928907 1:43804305-43804305 1:43338634-43338634
36 LOC106627981 NM_000157.4(GBA):c.1246G>A (p.Gly416Ser) SNV Pathogenic 4327 rs121908311 1:155205614-155205614 1:155235823-155235823
37 LOC106627981 NM_000157.4(GBA):c.653G>A (p.Trp218Ter) SNV Pathogenic 632834 rs867929413 1:155208033-155208033 1:155238242-155238242
38 MYH9 NM_002473.5(MYH9):c.4270G>A (p.Asp1424Asn) SNV Pathogenic 14082 rs80338831 22:36688106-36688106 22:36292060-36292060
39 SMAD4 NM_005359.6(SMAD4):c.904+1_904+2insGCCTGTTCACAA Insertion Pathogenic 988858 18:48584827-48584828 18:51058457-51058458
40 MED12L NM_022788.5(P2RY12):c.772C>A (p.Pro258Thr) SNV Pathogenic 988856 3:151055862-151055862 3:151338074-151338074
41 MED12L NM_022788.5(P2RY12):c.365G>A (p.Arg122His) SNV Likely pathogenic 988855 3:151056269-151056269 3:151338481-151338481
42 GP1BA NM_000173.7(GP1BA):c.413G>T (p.Gly138Val) SNV Likely pathogenic 988882 17:4836312-4836312 17:4933017-4933017
43 RUNX1 NM_001754.5(RUNX1):c.1270T>G (p.Ser424Ala) SNV Likely pathogenic 988867 21:36164605-36164605 21:34792308-34792308
44 RUNX1 NM_001754.5(RUNX1):c.403G>A (p.Gly135Ser) SNV Likely pathogenic 988857 21:36252959-36252959 21:34880662-34880662
45 CYCS NM_018947.6(CYCS):c.155C>T (p.Ala52Val) SNV Likely pathogenic 988874 7:25163584-25163584 7:25123965-25123965
46 GP1BA NM_000173.7(GP1BA):c.1274_1275del (p.Glu425fs) Deletion Likely pathogenic 988865 17:4837172-4837173 17:4933877-4933878
47 PTPN11 NM_002834.5(PTPN11):c.922A>G (p.Asn308Asp) SNV Likely pathogenic 13326 rs28933386 12:112915523-112915523 12:112477719-112477719
48 RUNX1 NM_001754.4(RUNX1):c.593A>T (p.Asp198Val) SNV Likely pathogenic 627342 rs1569061786 21:36231791-36231791 21:34859494-34859494
49 RUNX1 NM_001754.5(RUNX1):c.1270T>C (p.Ser424Pro) SNV Likely pathogenic 970259 21:36164605-36164605 21:34792308-34792308
50 RUNX1 NM_001754.4(RUNX1):c.611G>A (p.Arg204Gln) SNV Likely pathogenic 561253 rs1569061762 21:36231773-36231773 21:34859476-34859476

Expression for Thrombocytopenia

Search GEO for disease gene expression data for Thrombocytopenia.

Pathways for Thrombocytopenia

Pathways related to Thrombocytopenia according to KEGG:

36
# Name Kegg Source Accession
1 Tight junction hsa04530

GO Terms for Thrombocytopenia

Biological processes related to Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.73 SMAD4 RUNX1 MED12L FLI1 CHEK2 ACTN1
2 platelet degranulation GO:0002576 9.67 VWF ITGA2B ACTN1
3 blood coagulation GO:0007596 9.62 WAS VWF F11 ADAMTS13
4 platelet activation GO:0030168 9.61 VWF ADAMTS13 ACTN1
5 integrin-mediated signaling pathway GO:0007229 9.54 MYH9 ITGA2B ADAMTS13
6 actin filament-based movement GO:0030048 9.48 WAS MYH9
7 blood coagulation, intrinsic pathway GO:0007597 9.46 VWF F11
8 hematopoietic stem cell proliferation GO:0071425 9.4 RUNX1 ETV6
9 platelet formation GO:0030220 9.33 NBEAL2 MYH9 ACTN1
10 hemostasis GO:0007599 9.26 VWF FLI1 F11 ADAMTS13
11 platelet aggregation GO:0070527 8.92 MYH9 MPL ITGA2B ACTN1

Molecular functions related to Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 WAS VWF SMAD4 MYH9 ITGA2B F11
2 protein homodimerization activity GO:0042803 9.65 SMAD4 RUNX1 MYH9 CHEK2 ACTN1
3 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.35 SMAD4 RUNX1 GFI1B FLI1 ETV6
4 integrin binding GO:0005178 8.92 VWF MYH9 ADAMTS13 ACTN1

Sources for Thrombocytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....